Burning Point Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

Nanjing Jiangsu China

Primary Industry

Biotechnology

About

Established in 2019 and based in Nanjing, China, Burning Point operates as a new drugs developer that provides slow and controlled release formulations, complex injectables, and improved new drugs and innovative drugs. The company cooperates with China Pharmaceutical University, Nanjing University of Traditional Chinese Medicine and Nanjing University of Technology, etc. More than 50% employees of the core research team has PhD and master's degrees. And it has a 3000 square meter pharmacy research laboratory. In September 2019, Fosun Pharmaceutical and Aohong Pharmaceutical became the strategic partner of the company. In November 2022, the company awarded the title of high-tech enterprise. In June 2023, it closed series B round of funding from Sealand Innovation. The company provides pharmaceutical R&D services, including chemical API process, Chinese medicine and natural drug, and preparation process development, consistency evaluation, analysis and testing, clinical research, and registration filing. Its products include slow and controlled release formulations, complex injectables, and improved new drugs and innovative drugs.

Current Investors

Zijin Venture Capital, Yangtze River Capital, BGI Co-WIN Investment Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.bpbiopharm.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.